Symbols

NVCR

Novocure·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NVCR

Novocure Limited

A global oncology company that develops novel therapy for the treatment of solid tumor cancers including glioblastoma brain cancer

Industry

Healthcare Equipment and Supplies

Established Date

02/11/2000

Listing Date

10/02/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,605

Fiscal Year Ends

12-31

Website

www.novocure.com

Security Type

Common stock

Office address

No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF

Business

Introduction

Novocure Limited is a public limited liability company incorporated on 11 February 2000 under the laws of Jersey, Channel Islands. It is a global oncology company that has developed a proprietary platform technology known as Tumor Therapy Fields (TTFields), which uses electric fields to kill cancer cells. NovoCure's key commercial products include Optune Gio, Optune Lua and Optune Pax, which provide TTFields therapy through medical devices. The company's main focus is to drive commercial adoption of its products, obtain regulatory approval for new indications, and advance clinical programs aimed at improving overall survival in aggressive cancers. NovoCure sells its products in several countries, and a large portion of its revenue comes from markets in the United States, Germany, France and Japan.

Company Financials

EPS

NVCR has released its 2025 Q4 earnings. EPS was reported at -0.22, versus the expected -0.41, beating expectations. The chart below visualizes how NVCR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NVCR has released its 2025 Q4 earnings report, with revenue of 174.35M, reflecting a YoY change of 8.11%, and net profit of -24.50M, showing a YoY change of 62.84%. The Sankey diagram below clearly presents NVCR's revenue sources and cost distribution.